Antiplatelet medications and risk of intracranial hemorrhage in patients with metastatic brain tumors

Although intracranial hemorrhage (ICH) is frequent in the setting of brain metastases, there are limited data on the influence of antiplatelet agents on the development of brain tumor–associated ICH. To evaluate whether the administration of antiplatelet agents increases the risk of ICH, we performe...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Eric J., Patell, Rushad, Uhlmann, Erik J., Ren, Siyang, Southard, Hannah, Elavalakanar, Pavania, Weber, Griffin M., Neuberg, Donna, Zwicker, Jeffrey I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905695/
https://www.ncbi.nlm.nih.gov/pubmed/35086145
http://dx.doi.org/10.1182/bloodadvances.2021006470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905695/
https://www.ncbi.nlm.nih.gov/pubmed/35086145
http://dx.doi.org/10.1182/bloodadvances.2021006470

Ejemplares similares